Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Show other versions (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Bibliografske podrobnosti
Main Authors:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Format:	Journal article
Jezik:	English
Izdano:	2014

Podobne knjige/članki

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
od: Ruiz Garcia, V, et al.
Izdano: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
od: Galina Viktorovna Lukina, et al.
Izdano: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
od: M Connock, et al.
Izdano: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
od: Vera Nikolayevna Amirdjanova, et al.
Izdano: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
od: Evgeniy L'vovich Nasonov, et al.
Izdano: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
od: Emna Hannech, et al.
Izdano: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
od: Dmitry Evgenyevich Karateev, et al.
Izdano: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
od: T. V. Korotaeva, et al.
Izdano: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
od: Maria Majdan, et al.
Izdano: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
od: Mariusz Korkosz
Izdano: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
od: Smolen, JS, et al.
Izdano: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
od: Purcaru, O, et al.
Izdano: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
od: J Rosa, et al.
Izdano: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
od: Sh. F. Erdes
Izdano: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
od: Andrea Bassi, et al.
Izdano: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
od: José Alexandre Mendonça, et al.
Izdano: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
od: Stéphane Paul, et al.
Izdano: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
od: Mehmet Baysal, et al.
Izdano: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
od: Lindsey J. Wanberg, et al.
Izdano: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
od: Tanaka, Y, et al.
Izdano: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
od: Karine Arnoldovna Lytkina, et al.
Izdano: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
od: Karine Arnoldovna Lytkina, et al.
Izdano: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
od: Ian R White, et al.
Izdano: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
od: Ian R. White, et al.
Izdano: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
od: Vivian P. Bykerk, et al.
Izdano: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
od: Glatt, S, et al.
Izdano: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
od: Clóvis Dervil Appratto Cardoso Júnior, et al.
Izdano: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
od: I.L. Khalif, et al.
Izdano: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
od: Ranatunga S, et al.
Izdano: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
od: Piotr Wiland, et al.
Izdano: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
od: Acosta-Felquer ML, et al.
Izdano: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
od: P. I. Novikov, et al.
Izdano: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
od: Hazes, J, et al.
Izdano: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
od: A. Spadaro, et al.
Izdano: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
od: Wojciech Blonski, et al.
Izdano: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
od: O V Knyazev, et al.
Izdano: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
od: Yael Sharon, et al.
Izdano: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
od: R. Talotta, et al.
Izdano: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
od: Syuichi Koarada, et al.
Izdano: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
od: Jeffrey R. Curtis, et al.
Izdano: (2017-12-01)